News & Updates
Filter by Specialty:
Men with HR+ breast cancer have high breast cancer─specific mortality risk at 20 years
Breast cancer–specific mortality (BCSM) risk remains high over 20 years in men with stage I─III hormone receptor (HR)–positive breast cancer and the kinetics are different from those seen in women, a population-based study has shown.
Men with HR+ breast cancer have high breast cancer─specific mortality risk at 20 years
13 Mar 2024Current treatment considerations for precision medicine: Bridging scientific data to clinical practice
Precision medicine and tumour-agnostic approach are changing the landscape of non-small-cell lung cancer (NSCLC) and many other advanced solid tumours without satisfactory standard treatments. In an industry-sponsored meeting endorsed by the Hong Kong Society of Clinical Oncology, Professor Jürgen Wolf of the Center for Integrated Oncology, University of Cologne, Germany, lead investigator of an international phase II trial that led to the approval of capmatinib for advanced NSCLC harbouring MET exon 14 (METex14) skipping mutation, discussed the importance of panel molecular testing and targeted therapy in different solid tumours, focusing in particular on advanced NSCLC with actionable driver mutations, such as MET alterations.